Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’r...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news
Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Researchers at the CeMM Research Center for Molecular Medicine and partners in Budapest have studied the response to targeted leukemia therapy in unprecedented detail, using single-cell sequencing and epigenetic analysis. The paper published in Nature Communications uncovers a precise molecular program in patients with chronic lymphocytic leukemia (CLL) who start treatment with ibrutinib. While this program was shared by all patients, the speed of its execution differed widely. These results will help develop personalized strategies for manag...
Source: EurekAlert! - Cancer - January 29, 2020 Category: Cancer & Oncology Source Type: news
Idelalisib May Induce More Favorable Outcomes in Clinical Trial Participants, Versus Medicare Beneficiaries
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Jennifer A. Woyach, MD, on the Alliance A041702 Trial in Chronic Lymphocytic Leukemia
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition. (Source: CancerNetwork)
Source: CancerNetwork - January 2, 2020 Category: Cancer & Oncology Authors: Jennifer A. Woyach, MD Source Type: news
CLL Highlights From ASH 2019 CLL Highlights From ASH 2019
Dr William Wierda of MD Anderson Cancer Center reviews key studies on chronic lymphocytic leukemia therapies presented at the 2019 American Society of Hematology (ASH) meeting in Orlando, Florida.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news
Revolutionary two-pronged attack that's beating 'incurable' blood cancer
Professor Lelia Duley, 61, from Southwell in Nottinghamshire, is one of the patients involved in a drug combination trial to combat chronic lymphocytic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - December 28, 2019 Category: Consumer Health News Source Type: news
A 66-Year-Old Man With Leukemia: USMLE Question A 66-Year-Old Man With Leukemia: USMLE Question
A 66-year-old man is found to have chronic myelogenous leukemia after a routine office visit. What is the most appropriate initial treatment in this case?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2019 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news
Survival Up for Chronic Lymphocytic Leukemia 1995 to 2017
THURSDAY, Dec. 26, 2019 -- For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia& Lymphoma.
Rudolf Weide, M.D., from the Praxis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 26, 2019 Category: Pharmaceuticals Source Type: news
Cancer Drug Nilotinib Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson ' s disease, a new study finds.
In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news
Cancer Drug Shows Promise for Parkinson's Patients
MONDAY, Dec. 16, 2019 -- A drug used to fight chronic myeloid leukemia might also relieve symptoms of Parkinson ' s disease, a new study finds.
In a phase 2 clinical trial, researchers found that the drug nilotinib (brand name: Tasigna) increased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 16, 2019 Category: General Medicine Source Type: news
Chronic leukaemia drug breakthrough could cut side effects
Scientists at the South Australian Health and Medical Research Institute tested a drug on 150 cancer patients and said it was better tolerated than alternatives because it didn't attack healthy cells. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2019 Category: Consumer Health News Source Type: news
IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven etoclax data from Phase 2 CA...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news
Merck drops $2.7B on 26-year-old Burlington biotech
Drug giant Merck& Co. announced Monday that it will spend billions to buy a 26-year old biotech company that's struggled to bring a cancer drug to market.
Merck (NYSE: MRK) will spend approximately $2.7 billion to acquire Burlington-based ArQule Inc. (Nasdaq: ARQL).
The biotech's drug that's furthest along in clinical trials is in the mid-stage tests against relapsed or refractory chronic lymphocytic leukemia. ArQule is expected to disclose more clinical data at an industry conference Monday.
ArQule,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 9, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news
Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news
Frontline Triplet Regimen Induces Undetectable MRD in the Bone Marrow of Patients with CLL
The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news
